Close Menu

NIH funding

RADx-UP is funding multiple efforts to determine how marginalized groups, such as undocumented immigrants and those in rural areas, can access testing.

The contracts are for two lateral flow rapid antigen tests, a laboratory-based test to detect and identify SARS-CoV-2 variants, and a rapid RT-PCR test.

The funding will be used to increase production of SARS-CoV-2 test kits in Meridian's Canadian facility and to build a new two-line production facility in Ohio.

The total investment comes to more than $283 million for a program focused on COVID-19 testing of people disproportionately affected by the pandemic, the NIH said.

The test is designed to detect and visualize abnormal phosphorylated alpha-synuclein — a hallmark of synucleinopathies — in cutaneous nerve fibers.

The test, which is licensed to rHealth, monitors FVIII levels in the blood of patients with hemophilia A patients, who lack the clotting protein.

More than 25 academic, government, and private research institutions will be part of the network, which aims to speed up delivery of testing, therapies, and vaccines.

The money will be used to understand COVID-19 testing patterns in vulnerable populations and develop strategies to reduce testing disparities.

Some of the firms will receive money to speed up test development, while others will use the funds to expand their testing and manufacturing capacity.

The sequencing firm said infectious disease research, diagnostics, screening, and surveillance could all increase demand for its NGS products.